Pancreatic Neuroendocrine Neoplasm
Conditions
Keywords
Genetic Assay, Biomarkers
Brief summary
This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)
Detailed description
PRIMARY OBJECTIVE: I. To assess the frequency of germline mutations in patients with PanNEN. SECONDARY OBJECTIVES: I. To assess the rates of different types of germline mutations in patients PanNEN. II. To assess the rates of different types of variants of uncertain significance in patients with PanNEN. III. To estimate the rate of completion of genetic testing in patients who are offered prospective germline testing. EXPLORATORY OBJECTIVES: I. To examine attitudes of patients who have completed germline testing. II. To explore reasons for declining germline testing. III. In patients with repeat germline testing, compare the frequency of germline alteration between tests. IV. Assess the relationship between germline pathogenic variants and somatic mutations in PanNEN. OUTLINE: Potential eligible participants will be identified via chart review and invited to consent to the study. Study participants who agree to prospective testing and have not had previous large panel germline testing will watch an informational video about germline testing and be offered testing with University of California, San Francisco's (UCSF) Expanded Hereditary Cancer Panel. Study participants who decline germline testing will be asked to answer a one-question Declination Survey. Results will be shared with participants and their providers per the standard of practice at each participating study site. All participants who decided to receive germline testing will be asked to complete a decision survey.
Interventions
DIAGNOSTIC_TESTHereditary Cancer Panel
UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
Sponsors
University of California, San Francisco
University of California Pancreatic Cancer Consortium (UCPCC)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. Histologically confirmed PanNEN. a. The diagnostic biopsy may have been taken from any site (primary or metastatic). 2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years). 3. Participants willing and able to comply with the study procedures.
Exclusion criteria
1. Inability to provide informed consent. 2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes: 1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic). 2. Active hematologic malignancy. 3. History of allogenic bone marrow transplant or stem cell transplant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of overall pathogenic germline mutations | Up to 2 years | The overall percentage of participants with pathogenic, or likely pathogenic germline mutations will be reported with 95% confidence intervals |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rates of different types of pathogenic mutations | Up to 2 years | The percentage of participants with each identified type of pathogenic, or likely pathogenic, will be reported with 95% confidence intervals |
| Rates of different types of variants of uncertain significance (VUS) | Up to 2 years | The percentage of participants with identified variants of uncertain significance will be reported with 95% confidence intervals. |
| Rate of declination for participants offered testing. | Up to 2 years | Participants who decline genetic testing but agree to participate in other study procedures will complete a Declination Survey which consists of one questions asking the reason for the decision to decline germline testing. |
| Rate of completion of testing | Up to 2 years | The rate of study completion defined as the percentage of participants who agree to testing, and complete all study procedures through return of results and meeting with genetic counselor (as appropriate) will be reported. |
Countries
United States
Contacts
CONTACTBryan Le
PRINCIPAL_INVESTIGATOREmily Bergsland, MD
University of California, San Francisco
Outcome results
None listed